Arcus Biosciences (RCUS) Equity Average (2018 - 2026)

Arcus Biosciences has reported Equity Average for 9 years, with the latest figure at $577.5 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 13.68% year-over-year to $577.5 million; the trailing twelve-month figure through Mar 2026 stood at $577.5 million (up 13.68% YoY), and the FY2025 full-year result was $558.0 million, up 17.85% from the prior year.
• Equity Average for Q1 2026 stood at $577.5 million, up from $533.5 million in the prior quarter.
• The five-year high for Equity Average was $819.5 million in Q1 2022, with the low at $491.0 million in Q4 2023.
• Average Equity Average over 5 years is $604.1 million, with a median of $583.0 million recorded in 2023.
• Year-over-year, Equity Average surged 40.47% in 2022 and fell 27.58% in 2023.
• Tracing RCUS's Equity Average over 5 years: stood at $678.0 million in 2022, then dropped by 27.58% to $491.0 million in 2023, then gained by 6.92% to $525.0 million in 2024, then grew by 1.62% to $533.5 million in 2025, then grew by 8.25% to $577.5 million in 2026.
• The last three Equity Average figures came in at $577.5 million (Q1 2026), $533.5 million (Q4 2025), and $492.5 million (Q3 2025), per Business Quant data.

Peer Comparison